The Technical Analyst
UNITY Biotechnology Inc [UBX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
UNITY Biotechnology Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.33% $1.505
America/New_York / 19 apr 2024 @ 13:16
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 25.26 mill |
| EPS: | -2.70 |
| P/E: | -0.560 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 16.79 mill |
| Avg Daily Volume: | 0.0908 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.560 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.10x |
| Company: PE -0.560 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.486 (-132.32%) $-1.991 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.414 - 1.596 ( +/- 6.05%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-26 | Nguyen Alexander Hieu | Buy | 30 000 | Stock Option (Right to Buy) |
| 2024-03-26 | Nguyen Alexander Hieu | Buy | 20 000 | Common Stock, $0.0001 par value |
| 2024-02-02 | Ghosh Anirvan | Sell | 680 | Common Stock, $0.0001 par value |
| 2024-01-30 | Ghosh Anirvan | Sell | 1 183 | Common Stock, $0.0001 par value |
| 2023-11-02 | Ghosh Anirvan | Sell | 589 | Common Stock, $0.0001 par value |
| INSIDER POWER |
|---|
| 55.28 |
| Last 99 transactions |
| Buy: 2 792 498 | Sell: 401 244 |
Forecast:
14:58 - $1.503
Live Trading Signals (every 1 min)
Forecast
1: 13:28 - $1.504
Forecast 2: 14:18 - $1.503
Forecast 3: 14:58 - $1.503
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.505 (-0.33% ) |
| Volume | 0.0319 mill |
| Avg. Vol. | 0.0908 mill |
| % of Avg. Vol | 35.12 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For UBX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
UBX
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Latest Press Releases
2024-04-15 07:00:00 - Press Release
Unity Biotechnology, Inc. Reports Fourth Quarter And Full Year 2023 Financial Results And Business Updates
South san francisco, calif., april 15, 2024 (globe newswire) -- unity biotechnology, inc. (unity) [nasdaq:ubx], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended december 31, 2023.
2024-02-06 08:00:00 - Press Release
New Publication In Nature Medicine Supports Therapeutic Potential Of Senolytics To Provide Long-lasting, Disease-modifying Intervention In Vision Loss
South san francisco, calif., feb. 06, 2024 (globe newswire) -- unity biotechnology, inc. (“unity”) [nasdaq: ubx], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced new research published in the peer-reviewed journal nature medicine that supports the clearance of senescent cells in the retina as a therapeutic approach that can lead to long-term improvements in vision in patients with diabetic macular edema (dme). sustained hyperglycemia from diabetes induces cellular senescence which damages the retina, including the delicate vasculature in the eye. this can lead to fluid accumulation and retinal thickening – a key feature of dme...
2023-12-12 08:00:00 - Press Release
Unity Biotechnology Doses First Patients In Phase 2 Aspire Study Of Ubx1325 In Dme
South san francisco, calif., dec. 12, 2023 (globe newswire) -- unity biotechnology, inc. (“unity”) [nasdaq: ubx], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the first patients have been dosed in the phase 2 aspire study of ubx1325 (foselutoclax), a bcl-xl inhibitor being evaluated head-to-head against standard of care anti-vegf in patients with diabetic macular edema (dme).
2023-11-13 16:05:00 - Press Release
Unity Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
South san francisco, calif., nov. 13, 2023 (globe newswire) -- unity biotechnology, inc. (unity) [nasdaq:ubx], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended september 30, 2023.
2023-11-10 08:00:00 - Press Release
Unity Biotechnology Announces Exercise Of Warrants For $4.38 Million In Gross Proceeds
South san francisco, calif., nov. 10, 2023 (globe newswire) -- unity biotechnology, inc. (“unity” or the “company”) [nasdaq: ubx], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,143,000 shares of common stock, having an exercise price of $8.50 per share, issued by unity on august 22, 2022, at a reduced exercise price of $2.045 per share. the shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on form s-3 (file no. 333-263574)...
Latest News
2023-10-17 17:14:14 - InvestorPlace
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks
Longevity stocks have started to come on many investors' radars. These companies come with the promise of stable returns over the long run as human life continues to stretch further ahead.
2023-03-28 16:45:10 - Zacks Investment Research
Unity (UNX) Down on Disappointing Results From Wet AMD Study
Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.
2023-03-27 12:00:21 - InvestorPlace
Why Is Unity Biotechnology (UBX) Stock Down 52% Today?
Unity Biotechnology (NASDAQ: UBX ) stock is taking a beating on Monday after revealing results from its Phase 2 clinical trial of UBX1325. UBX1325 is a treatment in development by the company that it's testing for use with patients suffering from wet age-related macular degeneration ( AMD ).
2022-11-01 12:45:12 - InvestorPlace
Unity Biotechnology (UBX) Stock Pops on Positive Study Data
Unity Biotechnology (NASDAQ: UBX ) stock is gaining on Tuesday after the company released results from a Phase 2 clinical trial of UBX1325. UBX1325 is the company's treatment in development to treat patients dealing with diabetic macular edema (DME).
2022-10-24 08:15:00 - Seeking Alpha
Unity Biotechnology: Share Consolidation On The Back Of Positive Trial Results
A small cap biotech targeting diseases of ageing, with a lead compound focusing on ophthalmology that recently reported positive trial results. Not overly reliant on debt and has reported some revenues with relatively stable overall financials.
2022-10-10 13:32:25 - Zacks Investment Research
All You Need to Know About UNITY Biotechnology, Inc. (UBX) Rating Upgrade to Strong Buy
UNITY Biotechnology, Inc. (UBX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2022-09-19 07:00:01 - InvestorPlace
The Three Best Anti-Aging Stocks to Buy in September
Anti-aging stocks have not proven immune to poor market conditions that have plagued the broader biotech industry. The biotech industry remains hampered by the same bleak economic conditions as those affecting growth companies.
2022-08-31 08:00:00 - GlobeNewsWire
UNITY Biotechnology to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will participate in the following investor conferences in September.
2022-08-30 11:17:30 - Zacks Investment Research
Bears are Losing Control Over UNITY Biotechnology, Inc. (UBX), Here's Why It's a 'Buy' Now
UNITY Biotechnology, Inc. (UBX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
2022-08-15 06:00:00 - PennyStocks
Hot Penny Stocks to Add to Your Watchlist Right Now
Here's what you need to know about trading penny stocks on August 15th The post Hot Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.